AbbVie Inc. (ABBV) News

AbbVie Inc. (ABBV)

Today's Latest Price: $94.91 USD

1.87 (2.01%)

Updated Jun 5 2:06pm

Add ABBV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter ABBV News Items

ABBV News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

AbbVie's upadacitinib shows durable benefit in RA studies

AbbVie (ABBV) announces positive long-term results from two Phase 3 clinical trials, SELECT-COMPARE and SELECT-MONOTHERAPY, evaluating Rinvoq (upadacitinib) in rheumatoid arthritis ((RA)) patients. The data were presented at EULAR.Patients in the first study who received daily doses of 15 mg of upadacitinib with methotrexate continued to experience improved signs and...

Seeking Alpha | June 4, 2020

5 High-Yield Blue-Chips I'm Buying For My Retirement Portfolio In This Overvalued Market

(Source: Imgflip) Are you feeling a bit giddy right now? Perhaps even a tad euphoric? No one could blame you if you were, given how red hot the stock market has been over the past few months. S&P 500 & My Phoenix Portfolio's Top Winners Since March 23rd Low (Source:...

Dividend Sensei | June 4, 2020

Is AbbVie (ABBV) Outperforming Other Medical Stocks This Year?

Is (ABBV) Outperforming Other Medical Stocks This Year?

Zacks Investment Research | June 4, 2020

Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run

Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.

Yahoo | June 4, 2020

Top Ranked Value Stocks to Buy for June 4th

Top Ranked Value Stocks to Buy for June 4th

Yahoo | June 4, 2020

AbbVie Follows Up After Reversal

Similar action in AbbVie with a little flat area forming after following up on small reversal yesterday.

Yahoo | June 4, 2020

Signs That Your Trading Will Ruin Your Retirement - June 04, 2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

Yahoo | June 4, 2020

New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE (upadacitinib, 15 mg in combination with methotrexate [MTX]) and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively.1,2 The safety profile of upadacitinib (15 mg and 30 mg) monotherapy or upadacitinib (15 mg) in combination with MTX was consistent with that observed in the previously reported integrated Phase 3 safety analysis in rheumatoid arthritis, with no new safety risks detected.1-5

Yahoo | June 4, 2020

50-Day Rally Spells Good Times for Wall Street: 5 Solid Buys

With Wall Street notching a 50-day rally amid signs of the economic slump bottoming out and history hinting further gains, investing in stocks that are poised to gain in the near term seems judicious.

Yahoo | June 4, 2020

Dr. Keshav K. Singh Joins Allergan Aesthetics Science Of Aging(SM) Faculty

Yuva Biosciences, an anti-aging startup based on technology developed by one of the world leaders in mitochondrial sciences, Dr. Keshav K. Singh, is pleased to announce that Dr. Singh joined the Science of AgingSM faculty, a platform owned and run by Allergan Aesthetics Medicine R&D;.

Yahoo | June 4, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5914 seconds.